Roth Marc T, Cardin Dana B, Berlin Jordan D
Department of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
F1000Res. 2020 Feb 21;9. doi: 10.12688/f1000research.21981.1. eCollection 2020.
Pancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is projected to become a leading cause of cancer-related death in coming years. Improving quality of life and survival amongst these patients will require new ideas and novel therapies in a multidisciplinary approach. This review will cover the most recent advances in the comprehensive treatment of pancreatic cancer and place them within a historical context when necessary. Treatment of all disease stages will be discussed, but the focus is on systemic therapy as novel drugs and new treatment combinations enter the clinic. This will include more aggressive chemotherapy in earlier disease stages, approved uses for immunotherapy, and targetable mutations. In addition, negative trials of importance and controversial topics will be noted.
胰腺导管腺癌是最致命的实体瘤恶性肿瘤之一，预计在未来几年将成为癌症相关死亡的主要原因。要提高这些患者的生活质量和生存率，需要采用多学科方法提出新想法和开展新疗法。本综述将涵盖胰腺癌综合治疗的最新进展，并在必要时将其置于历史背景中。将讨论所有疾病阶段的治疗，但重点是随着新型药物和新的治疗组合进入临床，系统性治疗。这将包括在疾病早期阶段采用更积极的化疗、免疫疗法的获批用途以及可靶向的突变。此外，还将提及重要的阴性试验和有争议的话题。
